Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monoclonal Antibodies Against NKG2A

a monoclonal antibody and nkg2a technology, applied in the field of monoclonal antibodies, can solve the problems of preventing studies in nonhuman primates, and achieve the effect of reducing the number of nk cells in a cell population and reducing the nk cell-mediated lysis of cells

Inactive Publication Date: 2011-09-22
INNATE PHARMA SA +1
View PDF4 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]In another embodiment, the antibody of fragment thereof is derivatized to enhance its bioavailability or stability in vivo. In another embodiment, the antibody is derivatized with PEG.
[0036]The inhibitory antibody and fragments of this invention may be utilized in a method of reducing NK cell-mediated lysis of cells. Alternatively, the inhibitory antibody and fragments of this invention may be utilized in a method of reducing the number of NK cells in a cell population. Both of these methods comprise the step of contacting said NK cell with the inhibitor monoclonal antibody or fragment.

Problems solved by technology

However, studies in nonhuman primates can be impeded if an antibody directed against a human protein does not bind to the nonhuman animal homolog of the target protein.
As antibodies bind to specific 3-dimensional features of their targets, slight changes in the amino acid sequence of a target protein can abolish binding altogether, making it unpredictable whether a given antibody directed against a protein from one species will also bind to homologous proteins sharing some but not complete sequence identity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal Antibodies Against NKG2A
  • Monoclonal Antibodies Against NKG2A
  • Monoclonal Antibodies Against NKG2A

Examples

Experimental program
Comparison scheme
Effect test

example 1

Killing of Autologous iDC is Mediated by a Subset of CD94 / NKG2A+KIR-NK Cells

[0239]Polyclonal NK cells cultured in the presence of exogenous IL-2 were previously shown to display strong cytolytic activity against iDC. Accordingly, in the present study, polyclonal NK cell populations isolated from donors AM, AC and DB efficiently killed both autologous and allogeneic iDC. However, the cytolytic activity against autologous iDC could be incremented in the presence of appropriate anti-HLA class I mAb.

[0240]These data could be the consequence of the disruption of inhibitory interactions occurring between self HLA class I on DC and inhibitory receptors on NK cells. On the basis of these results, we formulated the hypothesis that only a fraction of the total NK cell pool displays spontaneous cytotoxicity against iDC whereas the other NK cells do not because of effective inhibitory interactions between their receptors and HLA class I molecules. To analyze this possibility, a panel of NK cell...

example 2

The Susceptibility of iDC to NK-Mediated Cytotoxicity Reflects the Down-Modulation of HLA-E Class I Molecules

[0247]Previous studies demonstrated that iDC and mDC display remarkable differences in terms of HLA class I surface expression. Thus, by the use of mAb specific for a monomorphic determinant of HLA-A, B, C and E molecules, it has been shown that DC undergoing maturation greatly up-regulate their HLA class I expression at the cell surface. Moreover, the up-regulation of HLA class I represented a crucial mechanism by which mDC become resistant to NK-cell-mediated lysis.

[0248]To directly assess the expression of various HLA class I molecules on cells representative of different stages of DC maturation we comparatively analyzed the expression of HLA-A, B, C and E on monocytes, iDC and mDC derived from the same individual. All HLA class I molecules were highly up-regulated in mDC as compared with iDC. Remarkably, they were clearly down-regulated in iDC as compared with monocytes (...

example 3

A Small Fraction of NK Clones can Mediate Killing of mDC

[0250]Consistent with previous reports that polyclonal NK cells do not efficiently kill mDC, we show that most NK cell clones that lysed iDC did not to kill mDC. Interestingly, however, mDC were lysed by a minor fraction of NK clones belonging to group A (i.e. those displaying spontaneous anti-iDC cytolytic activity that could not be increased by anti-HLA class I mAb). Lysis of autologous mDC was lower as compared with that of iDC and could be increased in the presence of anti-HLA class I mAb. This suggests that the higher expression of HLAE in mDC as compared with iDC results in a more effective signaling via CD94 / NKG2A (this is also suggested by the ability of anti-CD94 mAb to increase their lysis). Concerning group B NK clones (i.e. capable of killing iDC and whose lysis was incremented by anti-HLA class I mAb), they displayed no cytolytic activity again mDC; however, cytolytic activity could be revealed in the presence of a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
decay energyaaaaaaaaaa
decay energyaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. Ser. No. 11 / 720,553, filed May 31, 2007, which is the U.S. national stage application of International Patent Application No. PCT / IB2005 / 004013, filed Dec. 27, 2005, which claims the benefit of U.S. Provisional Patent Application No. 60 / 639,465, filed Dec. 28, 2004, and U.S. Provisional Patent Application No. 60 / 639,832 filed Dec. 28, 2004, the disclosures of which are hereby incorporated by reference in their entireties, including all figures, tables and amino acid or nucleic acid sequences.FIELD OF THE INVENTION[0002]The present invention relates to monoclonal antibodies and fragments thereof directed against the NK cell surface receptor NKG2A, as well as to methods of producing and evaluating such antibodies. The monoclonal antibodies and fragments thereof are useful in treating immune disorders, particularly autoimmune disorders, as well as other diseases requiring modulated NK cell function....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/28A61P35/00A61P31/00A61P31/12A61P37/00A61P29/00A61K39/00
CPCC07K16/2851A61K2039/505A61P1/00A61P1/04A61P1/16A61P13/12A61P17/00A61P17/06A61P17/14A61P19/02A61P21/00A61P21/04A61P25/00A61P27/02A61P29/00A61P31/00A61P31/12A61P35/00A61P35/02A61P37/00A61P37/02A61P37/04A61P37/06A61P37/08A61P43/00A61P5/14A61P7/00A61P7/06A61P9/00A61P9/10A61P3/10A61K39/395C07K16/00C07K16/28A61K39/39558A61K39/3955A61K45/06A61K2039/572C07K16/2896C07K2317/21C07K2317/76G01N33/56966G01N2333/70596G01N2500/04
Inventor MORETTA, ALLESSANDROMARCENARO, EMANUELAROMAGNE, FRANCOISANDRE, PASCALE
Owner INNATE PHARMA SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com